In the press

Matthew Read comments on CYN appointing Tufton in Investment Week

Biotech trusts top performance charts in February

Matthew Read comments on CYN’s appointment of Tufton as new manager in Jack Roach’s article:

“We think that shareholders will be reassured that this trust is retaining the team and process behind CYN’s recent strong performance, and that there will be no disruption to the trust’s strategy, risk profile, its enhanced 8% of NAV dividend policy, or the management fee, which remains in line with the reduced level introduced in 2025.”

Read the article here